JP2012526531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526531A5 JP2012526531A5 JP2012510276A JP2012510276A JP2012526531A5 JP 2012526531 A5 JP2012526531 A5 JP 2012526531A5 JP 2012510276 A JP2012510276 A JP 2012510276A JP 2012510276 A JP2012510276 A JP 2012510276A JP 2012526531 A5 JP2012526531 A5 JP 2012526531A5
- Authority
- JP
- Japan
- Prior art keywords
- orthopoxvirus
- anion exchange
- cell
- exchange adsorbent
- packaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 30
- 241000700629 Orthopoxvirus Species 0.000 claims description 22
- 239000003463 adsorbent Substances 0.000 claims description 19
- 238000005349 anion exchange Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000004806 packaging method and process Methods 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 101710163270 Nuclease Proteins 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 4
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 20
- 241000271566 Aves Species 0.000 claims 8
- 239000011148 porous material Substances 0.000 claims 5
- 108010017842 Telomerase Proteins 0.000 claims 4
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims 4
- 238000011026 diafiltration Methods 0.000 claims 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 238000005352 clarification Methods 0.000 claims 2
- 238000011118 depth filtration Methods 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 241000287828 Gallus gallus Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- -1 dimethylaminoethyl Chemical group 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 238000002523 gelfiltration Methods 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000001471 micro-filtration Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305422 | 2009-05-12 | ||
| EP09305422.9 | 2009-05-12 | ||
| US21348409P | 2009-06-12 | 2009-06-12 | |
| US61/213,484 | 2009-06-12 | ||
| PCT/EP2010/056491 WO2010130753A1 (en) | 2009-05-12 | 2010-05-11 | Method for orthopoxvirus production and purification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526531A JP2012526531A (ja) | 2012-11-01 |
| JP2012526531A5 true JP2012526531A5 (https=) | 2015-11-19 |
| JP5855564B2 JP5855564B2 (ja) | 2016-02-09 |
Family
ID=43084645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510276A Expired - Fee Related JP5855564B2 (ja) | 2009-05-12 | 2010-05-11 | オルソポックスウイルスの製造および精製方法 |
| JP2012510278A Ceased JP2012526532A (ja) | 2009-05-12 | 2010-05-11 | 不死化鳥類細胞系およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510278A Ceased JP2012526532A (ja) | 2009-05-12 | 2010-05-11 | 不死化鳥類細胞系およびその用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8609392B2 (https=) |
| EP (2) | EP2429580A1 (https=) |
| JP (2) | JP5855564B2 (https=) |
| KR (1) | KR20120026526A (https=) |
| CN (2) | CN103547285A (https=) |
| AU (2) | AU2010247371B2 (https=) |
| BR (2) | BRPI1007743A2 (https=) |
| CA (2) | CA2760465A1 (https=) |
| CR (1) | CR20110641A (https=) |
| IL (2) | IL216312A0 (https=) |
| NZ (1) | NZ596595A (https=) |
| RU (2) | RU2011148791A (https=) |
| SG (1) | SG176554A1 (https=) |
| WO (2) | WO2010130756A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009132195A1 (en) * | 2008-04-23 | 2009-10-29 | Michigan State University | Immortal avian cell line and methods of use |
| US8609392B2 (en) * | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| CN102807969B (zh) * | 2011-06-03 | 2013-09-25 | 中国科学院动物研究所 | 高产杆状病毒的转基因卵巢细胞系及其制备方法和应用 |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一） |
| WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| US20150141620A1 (en) * | 2012-06-01 | 2015-05-21 | Momenta Pharmaceuticals, Inc. | Methods related to rituximab |
| WO2013181575A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
| TWI638829B (zh) | 2012-07-10 | 2018-10-21 | 法商傳斯堅公司 | 分枝桿菌抗原疫苗 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| EP2970398B1 (en) | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| GB201310031D0 (en) * | 2013-06-05 | 2013-07-17 | Pirbright Inst The | Cell |
| CN105612250A (zh) * | 2013-10-07 | 2016-05-25 | 诺华股份有限公司 | 经处理的滤器 |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| KR102507483B1 (ko) * | 2014-12-01 | 2023-03-07 | 트랜스진 | 안정한 액체 백시니아 바이러스 제제 |
| EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
| EP4523756A3 (en) | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| WO2017172890A1 (en) | 2016-03-29 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion rsv f proteins and their use |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| US11084850B2 (en) | 2016-12-16 | 2021-08-10 | The Pirbright Institute | Recombinant prefusion RSV F proteins and uses thereof |
| CN110168092A (zh) | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3062549A1 (en) * | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3833745A1 (en) | 2018-08-10 | 2021-06-16 | REGENXBIO Inc. | Scalable method for recombinant aav production |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| AU2019336940B2 (en) | 2018-09-06 | 2025-09-11 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| CN112912518A (zh) | 2018-10-15 | 2021-06-04 | 再生生物股份有限公司 | 用于测量复制缺陷型病毒载体和病毒的感染性的方法 |
| US20220056481A1 (en) | 2018-12-28 | 2022-02-24 | Transgene | M2-defective poxvirus |
| CN111763661B (zh) * | 2019-04-02 | 2022-07-29 | 普莱柯生物工程股份有限公司 | 一种病毒纯化的方法、制备的疫苗组合物及其应用 |
| FI3953483T3 (fi) | 2019-04-11 | 2023-11-30 | Regenxbio Inc | Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi |
| TW202332458A (zh) | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
| CN112143693B (zh) * | 2019-06-28 | 2024-12-27 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
| CN110468107A (zh) * | 2019-08-09 | 2019-11-19 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种对jev易感的猪扁桃体细胞系 |
| CN110396502A (zh) * | 2019-08-09 | 2019-11-01 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 对jev易感的猪扁桃体细胞系的构建方法 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| EP3871690A1 (en) * | 2020-02-27 | 2021-09-01 | Technische Hochschule Mittelhessen | Method for virus production |
| JP7712284B2 (ja) | 2020-03-12 | 2025-07-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスの安定性を改善する組成物 |
| CN116322740A (zh) | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| CN116590346B (zh) * | 2020-09-15 | 2024-05-14 | 上海药明巨诺生物医药研发有限公司 | 一种慢病毒载体纯化方法 |
| EP4263841A1 (en) | 2020-12-16 | 2023-10-25 | REGENXBIO Inc. | Method of producing a recombinant adeno-associated virus particle |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| JP2024503895A (ja) | 2021-01-21 | 2024-01-29 | リジェネクスバイオ インコーポレイテッド | 組換えポリペプチド及びウイルスの生成の改善 |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
| WO2023114816A1 (en) | 2021-12-14 | 2023-06-22 | Neurogene, Inc. | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
| GB202201242D0 (en) | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
| US20250213727A1 (en) | 2022-03-25 | 2025-07-03 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| GB202206336D0 (en) | 2022-04-29 | 2022-06-15 | Univ Edinburgh | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
| CA3260379A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
| AU2023298083A1 (en) | 2022-06-29 | 2025-01-09 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| US20260049291A1 (en) | 2022-08-18 | 2026-02-19 | Transgene | Chimeric poxviruses |
| IL322961A (en) * | 2023-03-10 | 2025-10-01 | Bavarian Nordic As | Production of smallpox viruses from cell cultures |
| WO2024211780A1 (en) | 2023-04-07 | 2024-10-10 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024233529A2 (en) | 2023-05-07 | 2024-11-14 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2025090962A1 (en) | 2023-10-25 | 2025-05-01 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2025106374A1 (en) | 2023-11-13 | 2025-05-22 | Juno Therapeutics, Inc. | Aav production method |
| CN118109517A (zh) * | 2024-02-04 | 2024-05-31 | 南京市第一医院 | 一种永生化人结直肠癌成纤维细胞系及其构建方法和应用 |
| WO2026017965A1 (en) | 2024-07-19 | 2026-01-22 | The University Court Of The University Of Edinburgh | Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| US6007806A (en) | 1986-08-13 | 1999-12-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| EP0710288B1 (en) | 1993-06-10 | 2006-04-05 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| US5672485A (en) * | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| DE19730989A1 (de) | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| JP5322252B2 (ja) * | 2001-12-20 | 2013-10-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | 感染細胞からのポックスウイルスの採取および精製法 |
| US20040106184A1 (en) * | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| US7695960B2 (en) | 2003-06-05 | 2010-04-13 | Transgene S.A. | Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| JP4672659B2 (ja) | 2003-07-21 | 2011-04-20 | トランジェーヌ、ソシエテ、アノニム | 改善されたシトシンデアミナーゼ活性を有するポリペプチド |
| DK1646715T3 (da) | 2003-07-22 | 2010-08-16 | Vivalis | Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| ES2349483T3 (es) * | 2006-01-05 | 2011-01-04 | Transgene Sa | Transcriptasa inversa de la telomerasa aviar. |
| PL1979474T3 (pl) * | 2006-01-05 | 2011-01-31 | Transgene Sa | Ptasia odwrotna transkryptaza o charakterze telomerazy |
| BRPI0710242A2 (pt) | 2006-04-21 | 2011-08-09 | Transgene Sa | uso de uma composição |
| DK2029756T3 (en) * | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| EP1985305A1 (en) * | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| JP2010526546A (ja) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
| US8003363B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| JP5421250B2 (ja) * | 2007-07-03 | 2014-02-19 | トランスジーン ソシエテ アノニム | トリ不死化細胞株 |
| RU2503717C2 (ru) | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| HRP20150360T1 (hr) | 2007-11-19 | 2015-05-08 | Transgene Sa | Poksvirusni onkolitiäśki vektori |
| CN102257134B (zh) * | 2008-02-12 | 2014-03-05 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| JP5653223B2 (ja) * | 2008-02-25 | 2015-01-14 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 連続細胞系の生成方法 |
| US20110229969A1 (en) * | 2008-06-25 | 2011-09-22 | Volker Sandig | Cell Line for Propagation of Highly Attenuated AlphaViruses |
| US8609392B2 (en) * | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
-
2010
- 2010-05-11 US US13/319,874 patent/US8609392B2/en not_active Expired - Fee Related
- 2010-05-11 JP JP2012510276A patent/JP5855564B2/ja not_active Expired - Fee Related
- 2010-05-11 AU AU2010247371A patent/AU2010247371B2/en not_active Ceased
- 2010-05-11 EP EP10721439A patent/EP2429580A1/en not_active Withdrawn
- 2010-05-11 EP EP10718219A patent/EP2429579A1/en not_active Withdrawn
- 2010-05-11 BR BRPI1007743A patent/BRPI1007743A2/pt not_active IP Right Cessation
- 2010-05-11 KR KR20117029009A patent/KR20120026526A/ko not_active Withdrawn
- 2010-05-11 CA CA2760465A patent/CA2760465A1/en not_active Abandoned
- 2010-05-11 WO PCT/EP2010/056497 patent/WO2010130756A1/en not_active Ceased
- 2010-05-11 US US12/777,731 patent/US8445270B2/en not_active Expired - Fee Related
- 2010-05-11 RU RU2011148791/02A patent/RU2011148791A/ru not_active Application Discontinuation
- 2010-05-11 JP JP2012510278A patent/JP2012526532A/ja not_active Ceased
- 2010-05-11 WO PCT/EP2010/056491 patent/WO2010130753A1/en not_active Ceased
- 2010-05-11 CN CN201080021253.7A patent/CN103547285A/zh active Pending
- 2010-05-11 CN CN2010800316470A patent/CN102740881A/zh active Pending
- 2010-05-11 SG SG2011082518A patent/SG176554A1/en unknown
- 2010-05-11 CA CA 2761457 patent/CA2761457A1/en not_active Abandoned
- 2010-05-11 BR BRPI1007744A patent/BRPI1007744A2/pt not_active IP Right Cessation
- 2010-05-11 RU RU2011148790/10A patent/RU2560976C2/ru not_active IP Right Cessation
- 2010-05-11 AU AU2010247374A patent/AU2010247374A1/en not_active Abandoned
- 2010-05-11 NZ NZ59659510A patent/NZ596595A/xx not_active IP Right Cessation
-
2011
- 2011-11-10 IL IL216312A patent/IL216312A0/en unknown
- 2011-11-10 IL IL216310A patent/IL216310A0/en unknown
- 2011-11-29 CR CR20110641A patent/CR20110641A/es unknown
-
2013
- 2013-02-25 US US13/775,314 patent/US8778675B2/en not_active Expired - Fee Related
- 2013-11-12 US US14/077,621 patent/US9012198B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526531A5 (https=) | ||
| RU2011148790A (ru) | Способ продуцирования и очистки ортопоксвируса | |
| JP2009034115A5 (https=) | ||
| CN104862267B (zh) | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 | |
| US11629339B2 (en) | Aseptic purification process for viruses | |
| JP2005532779A5 (https=) | ||
| CA2859916C (en) | Purification of herpes virus | |
| JP2010275321A5 (https=) | ||
| KR20030032923A (ko) | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 | |
| JP6385559B2 (ja) | 細胞培養体からのポリオウイルスの精製プロセス | |
| TW201311896A (zh) | 製備病毒抗原及疫苗之方法 | |
| US11999975B2 (en) | Method for purifying an enveloped virus | |
| CN103571800B (zh) | 一种去除疫苗中宿主dna的方法 | |
| AU2004249802A1 (en) | Improvements in virus production | |
| CN102533679A (zh) | 一种病毒释放缓冲液的制备及其应用 | |
| JP2022508156A5 (https=) | ||
| KR102857126B1 (ko) | 금속 이온 처리에 의한 구제역 백신 항원의 생산성 향상 방법 | |
| CN102190701A (zh) | 一种流感病毒血凝素大规模分离纯化方法 | |
| JP6467139B2 (ja) | 狂犬病ウイルスの複製促進・増強方法 | |
| WO2007138689A1 (ja) | 鳥類由来細胞用の培養液、及び培養方法 | |
| AU2007221746A1 (en) | Improvements in virus production |